Vitamin C, Pain and Opioid Use Disorder - PMC
Summary
This article explores the potential of Vitamin C (ascorbic acid, AA) in managing pain and opioid use disorder (OUD). It reviews scientific literature, highlighting AA's antioxidant, anti-inflammatory, and cofactor roles in metabolic pathways crucial for mental health, stress response, and pain perception. The paper discusses AA's demonstrated safety and efficacy in pain relief across various clinical settings and its potential to reduce opioid dependency, withdrawal symptoms, and cravings. While acknowledging the need for further trials, it suggests AA as a promising, affordable, and well-tolerated adjunctive therapy for OUD.
Key Insights
Vitamin C shows significant promise as an adjunctive therapy for managing Opioid Use Disorder (OUD).
Research suggests Vitamin C (ascorbic acid, AA) can play a crucial role in managing Opioid Use Disorder (OUD). Studies in animal models and human clinical trials indicate that AA can reduce opioid tolerance and dependence, mitigate withdrawal symptoms, and potentially decrease cravings. Its antioxidant, anti-inflammatory, and co-factor properties are believed to contribute to its effectiveness in supporting neurological function and stress response, which are often compromised in individuals with OUD. The article posits that AA, particularly in its buffered sodium ascorbate form, is a safe, well-tolerated, and affordable option that could be integrated into comprehensive OUD treatment plans, potentially acting as a catalyst for healing and recovery. However, the authors emphasize the need for further clinical trials to fully establish its efficacy and optimal dosing protocols.
Vitamin C demonstrates both analgesic properties and a capacity to reduce opioid requirements, suggesting a preventative role in Opioid Use Disorder.
The article details how Vitamin C (AA) has proven safe and effective in providing pain relief across various clinical contexts, including surgical, oncological, and chronic pain. By effectively managing pain, AA can reduce the need for opioid analgesics. Given that many individuals develop Opioid Use Disorder (OUD) through the initial use of prescription painkillers, AA's ability to temper the need for these medications is significant. Furthermore, studies suggest AA can interrupt the neurochemistry of opioid tolerance and dependency. This dual action – providing pain relief and potentially preventing the development of tolerance and dependence – positions AA as a valuable tool in the prevention of OUD, thereby addressing a critical aspect of the ongoing opioid crisis.
Sections
Introduction to Vitamin C and its Role
Humans cannot synthesize Vitamin C (AA); it's an essential exogenous nutrient vital for numerous metabolic pathways.
Humans, along with primates, bats, and guinea pigs, lack the enzyme L-gulonolactone oxidase (GLO), which is necessary for the final step in synthesizing ascorbate. This inability makes exogenous AA a required nutrient for human health. Primarily recognized for its immune-boosting effects, AA also plays important roles in the central nervous system (CNS) concerning pain perception and stress adaptation. It has been shown to reduce the need for painkillers post-surgery, potentially prevent chronic pain conditions, and lower the required doses of opiates for pain management, possibly even preventing complex regional pain syndrome (CRPS).
Vitamin C aids in pain management and may prevent opioid tolerance and dependency.
Vitamin C has demonstrated benefits in tempering the need for painkillers after surgery and reducing the risk of chronic pain developing after acute injury. Individuals taking vitamin C can use lower doses of opiates for pain management and may even avoid complex regional pain syndrome (CRPS). The analgesic benefits of AA are evident in acute postoperative pain, cancer-related pain, and chronic non-cancer pain. These properties lead to the investigation of whether vitamin C can also prevent or treat opioid use disorder (OUD), as animal studies and clinical trials suggest it interrupts the neurochemistry of opioid tolerance and dependency, and mitigates withdrawal symptoms.
The Opioid Crisis: Epidemiological Context
Opioid overdose is a leading cause of death in the US, surpassing other causes and impacting all demographics.
Drug overdose is the primary cause of death for Americans under 50. Opioids are implicated in more overdose deaths than any other drug class, exceeding fatalities from guns, breast cancer, or car accidents. The opioid epidemic has become the deadliest drug crisis in American history, but this statistic only accounts for deaths, not the millions who survive overdoses or suffer the consequences of addiction. The reach of opioid addiction has expanded from urban centers to suburban and rural areas, with a significant proportion of individuals in treatment reporting that their addiction began with legal prescription painkillers.
OUD is characterized by intense cravings and severe withdrawal symptoms, making cessation difficult.
Once an individual develops Opioid Use Disorder (OUD), any interruption in their opioid use can trigger intense cravings and severe withdrawal symptoms. These symptoms can include excruciating body pains, abdominal cramping, diarrhea, nausea, vomiting, sweating, lacrimation, agitation, insomnia, hypertension, and tachycardia. These debilitating effects make it extremely challenging for individuals with OUD to discontinue their drug use, perpetuating the cycle of addiction.
Studies in Animal Models Exploring Vitamin C's Role in Opioid Use Disorder
Rats treated with Vitamin C self-administered less morphine and showed fewer withdrawal signs.
In a study involving rats that could self-administer morphine, those that received Vitamin C (AA) took fewer doses of morphine on average and exhibited fewer signs of withdrawal when the drug was discontinued, compared to a control group. This suggests that AA may reduce the reinforcing effects of morphine and attenuate withdrawal symptoms.
Pre-treatment with Vitamin C in mice reduced opioid tolerance and dependence, potentially mediated by dopaminergic and glutamatergic pathways.
Similar rat studies demonstrated that mice pre-treated with AA were significantly less likely to develop tolerance and dependence when administered morphine. The protective effect of AA was dose-dependent, and researchers hypothesized that dopaminergic and glutamatergic mechanisms are involved in mediating these protective actions.
Vitamin C inactivated opioid stereospecific binding in guinea pigs, suggesting a direct interaction with opioid receptors.
Studies in guinea pigs, which, like humans, cannot synthesize AA, explored the mechanisms by which vitamin C might prevent or treat opioid tolerance and dependence. Ascorbic acid treatment inhibited the morphine withdrawal response, and crucially, AA was found to irreversibly inactivate opioid stereospecific binding in guinea pig brain homogenates. This inactivation occurred in two phases: a rapid phase destroying up to 50% of binding within 60 seconds, followed by a slower phase. These findings suggest that vitamin C supplementation could potentially reduce and prevent opioid drug tolerance, craving, and physical dependence.
Human Clinical Trials Supporting Vitamin C in Pain Management
Vitamin C is a safe and effective adjunctive therapy for acute and chronic pain relief, potentially reducing opioid reliance.
Overall, vitamin C has been established as a safe and effective adjunctive therapy for managing both acute and chronic pain across various settings. Considering that opioid tolerance and dependency often stem from the medication or self-medication of pain, natural analgesics like AA are considered highly valuable in preventing and mitigating OUD in humans. This aligns with the observation that animals capable of synthesizing AA increase its production under stress or disease, and also when administered analgesics, mirroring how human AA blood levels drop after trauma and surgery, indicating increased demand.
In surgical settings, Vitamin C administration reduced the need for opioid analgesics post-operation.
Clinical trials have shown that administering vitamin C is associated with a reduced requirement for opioid analgesics in surgical contexts. For example, one randomized trial found that patients receiving a single dose of oral vitamin C prior to surgery required significantly less morphine for pain management in the first 24 hours compared to a placebo group. Similar beneficial outcomes on postoperative pain were observed with intravenous vitamin C administration in other studies, reinforcing its utility in reducing opioid use after surgical procedures.
Vitamin C can help manage cancer-related pain and improve quality of life by reducing opioid reliance.
Studies involving high doses of Vitamin C (AA) have indicated its potential to alleviate cancer-related pain and enhance the quality of life for patients. In some cases, AA administration led to a reduced or eliminated need for opiates in patients with advanced cancer and skeletal metastases. However, one pilot study failed to show significant benefits with a lower dosing protocol, suggesting that higher doses and longer durations of vitamin C therapy might be necessary for managing chronic pain in opioid users.
For chronic non-cancer pain, high doses of Vitamin C have demonstrated analgesic properties, including in conditions like neuralgia and CRPS.
Individuals experiencing chronic non-cancer pain are at a significant risk of developing opioid use disorder (OUD), with a substantial percentage becoming addicted to prescribed opioids. Clinical trials have shown that high doses of vitamin C, particularly when administered intravenously, can mitigate the pain associated with various chronic pain conditions. This includes acute and post-herpetic neuralgia, and complex regional pain syndrome (CRPS). Vitamin C may even help prevent the development of CRPS following acute fractures, indicating broad analgesic potential beyond OUD management.
Clinical Trials of Vitamin C to Decrease Opioid Withdrawal in OUD
Large doses of AA have been reported to suppress opioid withdrawal symptoms in individuals with OUD.
Testimonies from studies and clinical observations indicate that high doses of ascorbic acid (AA) can effectively suppress the signs and symptoms of opioid withdrawal in individuals suffering from Opioid Use Disorder (OUD). This suggests a potential therapeutic role for AA in managing the challenging withdrawal phase.
A human study showed Vitamin C and E supplementation significantly reduced withdrawal symptoms in heroin addicts compared to diazepam and analgesic treatment.
In a human study involving individuals with heroin addiction, oral supplementation with vitamin C and vitamin E led to significant reductions in withdrawal symptoms for a majority of patients. In contrast, the control group receiving diazepam and an analgesic showed minimal improvement. This highlights the potential superiority of vitamin C and E in alleviating withdrawal compared to conventional treatments.
Buffered vitamin C significantly offset withdrawal symptoms in patients detoxifying from stimulants and opiates.
A trial conducted at the Haight-Ashbury Free Clinic found that daily doses of buffered vitamin C (1 to 3 g) significantly reduced withdrawal symptoms in patients detoxifying from stimulants and opiates. A substantial portion of patients reported major symptom relief, with even greater benefits observed in those undergoing aftercare, suggesting sustained positive effects.
Case Reports on Tapering Down and Quitting Opioids with Vitamin C
Dr. Alexander Schauss developed a protocol using high-dose sodium ascorbate (SA) to enable abrupt opioid discontinuation without withdrawal.
In 1969, Alexander G. Schauss, PhD, developed a protocol using high doses of sodium ascorbate (SA) to help individuals addicted to heroin 'quit cold turkey' without experiencing withdrawal symptoms. Based on findings that vitamin C could occupy opioid receptor sites, Schauss tested this concept in humans. His protocol involved progressively increasing SA doses over several days before initiating withdrawal, with continued SA administration to manage any emerging symptoms. This approach was observed to abort heroin withdrawal signs and symptoms in all subjects.
Schauss's protocol led to subsequent successes by other clinicians and researchers, though official endorsement was limited.
Following Schauss's initial study, numerous scientists and clinicians reported successful outcomes using his SA protocol or similar variations, sometimes incorporating niacin. Despite anecdotal evidence of the protocol's efficacy, including its observation by representatives from the National Institute on Drug Abuse and Alcoholism (NIDAA), official endorsement was not granted, which Schauss attributed to potential conflicts of interest within the review process.
Libby and Stone reported successful OUD treatment using high-dose SA alongside other supplements, achieving a 100% success rate in a pilot study.
Drs. Alfred F. Libby and Irwin Stone presented case reports in 1977 detailing their protocol for treating heroin addiction. They used high doses of sodium ascorbate (SA) daily (25-85 g), along with other vitamins, minerals, and predigested proteins. Their method aimed to help patients discontinue opiates abruptly. The protocol reported a 100% success rate in their pilot study, with patients experiencing appetite return, restful sleep, and overall well-being. Doses were gradually reduced after the initial treatment period.
A case within Libby and Stone's report involved a patient who experienced no effect from a large heroin dose while on high-dose SA.
One compelling case report from Libby and Stone described a 24-year-old male with a nine-year history of heroin use who had failed multiple detoxification attempts and was on methadone maintenance. Despite his skepticism, the patient experienced profound benefits from the SA protocol. Notably, after taking 45g of sodium ascorbate, he took a large dose of heroin but felt no effect. He continued the high-dose SA followed by a tapering dose, remaining drug-free with a sense of well-being.
Trevor Millar adapted Schauss's protocol for gradual opioid tapering, showing significant success in patient outcomes.
Trevor Millar, working in Vancouver, Canada, primarily supports patients in gradually tapering their opioid usage rather than quitting abruptly. He adapted Schauss's protocol by having patients take SA at a dose of 2g every 2 waking hours for 3 days before initiating opioid dose reduction. The SA dose could be increased as needed to manage withdrawal symptoms. Millar shared case reports of remarkable success, including a patient significantly reducing their buprenorphine dosage and another achieving sobriety from high-dose morphine, hydromorphone, and street fentanyl.
Millar's patient 'Lucy' reported immediate relief from withdrawal symptoms and made substantial progress in tapering her opioid regimen with SA.
Millar's case report of a patient named 'Lucy', who was using high doses of extended-release morphine sulfate, injectable hydromorphone, and daily street fentanyl, illustrates the effectiveness of the adapted SA protocol. Upon starting 2g of SA every 2 waking hours, Lucy reported waking the next morning with no withdrawal symptoms and feeling better than she had in years. She has since made significant progress in reducing her opioid dosages, working closely with her physician, and is nearing complete discontinuation from opioids.
Proposed Mechanisms of Action for Vitamin C in Opioid Use Disorder
Vitamin C addresses nutritional deficiencies common in substance abuse, potentially ameliorating OUD.
Chronic substance abuse often leads to deficiencies in vitamins, minerals, and amino acids. Studies show individuals entering drug addiction treatment have high rates of nutrient deficiencies, particularly in antioxidant vitamins like C and E. Opiate drugs specifically can impair gastrointestinal function, further exacerbating nutritional deficits. Some researchers describe OUD as a 'Hypoascorbemia-Kwashiorkor type of syndrome', suggesting that correcting vitamin C deficiency might be a fundamental aspect of treating the disorder.
As a potent antioxidant, Vitamin C protects the CNS from oxidative damage, which is common in addiction and linked to mental health issues.
Vitamin C is a powerful antioxidant that defends body cells, including those in the CNS, against oxidative damage caused by reactive oxygen species (ROS). Oxidative stress can impair neurological function and is linked to various psychiatric disorders such as anxiety, depression, and bipolar disorder. Individuals addicted to heroin exhibit high rates of oxidative injury, with their condition correlating with decreased levels of vitamin C and other antioxidants. By reducing oxidative stress, AA may improve mental health and support recovery from OUD, especially considering the high co-occurrence of OUD with anxiety and depression.
Vitamin C's anti-inflammatory properties may benefit mood regulation and counter inflammation associated with mood disorders.
Oxidative stress and inflammation are closely linked, and elevated inflammatory markers are often observed in individuals with mood disorders. Vitamin C has been shown to decrease levels of C-reactive protein (CRP) and reduce pro-inflammatory cytokines. Since conventional antidepressant drugs are thought to exert some of their effects through anti-inflammatory and antioxidant actions, AA's anti-inflammatory capabilities further support its role in improving mood and potentially aiding in OUD recovery, especially in individuals who also suffer from anxiety or depression.
Vitamin C acts as a glutathione recycler, helping to reverse opiate-induced damage.
The use of opiates can lead to glutathione depletion, a process that may contribute to the development and perpetuation of drug dependency. Vitamin C plays a role in maintaining glutathione concentrations, particularly in red blood cells and liver cells. Studies have shown that vitamin C supplementation can significantly increase red blood cell glutathione levels. Furthermore, both vitamin C and glutathione have been demonstrated to completely reverse opiate-induced liver damage in animal models, suggesting that combating oxidative damage through glutathione recycling is a promising therapeutic strategy for opiate abuse.
Vitamin C is crucial for adrenal health and moderates cortisol response during stress, vital for OUD recovery.
In mammals that synthesize vitamin C, stress and disease significantly increase its production. Humans, unable to synthesize AA, rapidly deplete their adrenal stores during stressful situations, as AA is stored in high concentrations in the adrenal glands and is secreted with cortisol in response to stress. Supplementation with vitamin C has been associated with a reduced cortisol response to stress and may play a modulating role in adrenal steroid production. Given that substance use disorder often originates from maladaptation to stress and trauma, supporting adrenal health through AA supplementation is critical for OUD prevention and treatment.
AA influences catecholamine biosynthesis, supporting neurotransmitter balance relevant to mood and pain.
Ascorbic acid (AA) functions as a cofactor in the biosynthesis of catecholamines, specifically in the conversion of dopamine to norepinephrine. AA deficiency is linked to reduced catecholamine levels and diminished epinephrine response. It also aids in dopamine and serotonin synthesis by recycling tetrahydrobiopterin. This role in neurotransmitter metabolism is significant, as imbalances in these systems are implicated in OUD, pain perception, and mood disorders. By supporting the endogenous synthesis of these neurotransmitters, AA may contribute to analgesia and improved mood.
Vitamin C modulates dopaminergic and glutamatergic systems involved in opiate tolerance and withdrawal.
The dopaminergic and glutamatergic systems in the brain are known to be involved in the development of opiate tolerance and withdrawal symptoms. Research indicates that Vitamin C can modulate the actions of these neurotransmitters in the rat brain. AA is released from glutamatergic neurons and influences the synaptic actions of both dopamine and glutamate. This modulation offers another pathway through which AA may counteract addictive behaviors associated with opioid use.
AA may enhance the synthesis of analgesic opioid peptides, indirectly aiding pain management and OUD.
Vitamin C is a cofactor for peptidylglycine α-amidating monooxygenase (PAM), an enzyme critical for modifying peptide hormone precursors. Some amidated neuropeptides have potent opioid activity, and AA administration can enhance the production of PAM-derived hormones. For example, calcitonin, an amidated peptide hormone, has analgesic effects on bone pain and complex regional pain syndrome. Therefore, vitamin C repletion could enhance the synthesis of analgesic peptides like endomorphins and indirectly influence endorphin levels, contributing to pain relief and potentially aiding in OUD treatment.
Safety of High-Dose Vitamin C Supplementation
Buffered Vitamin C (sodium ascorbate) is well-tolerated and avoids gastrointestinal upset associated with regular ascorbic acid.
While high doses of regular ascorbic acid (AA) can cause osmotic diarrhea, buffered vitamin C, such as sodium ascorbate (SA), is a well-tolerated alternative that does not typically induce gastrointestinal distress. SA was the form used in significant historical studies for OUD and pain management, highlighting its suitability for high-dose administration. The alkalinizing substances present in buffered vitamin C supplements may also offer additional health and detoxification benefits.
High-dose Vitamin C supplementation has few risks, mainly contraindications for specific patient groups.
The risks associated with high-dose vitamin C supplementation are generally minimal. However, it is contraindicated in individuals with renal insufficiency, those on chronic hemodialysis, patients with iron overload conditions, and those prone to oxalate stone formation. While findings on vitamin C and stone risk are mixed, some studies indicate a higher risk in men. AA significantly enhances iron absorption, posing a risk for individuals with hemochromatosis. Intravenous vitamin C in patients with G6PD deficiency is also controversial due to potential hemolysis risk.
The risks of Vitamin C are generally lower than those associated with conventional OUD medications.
When considering the risks and benefits of high-dose vitamin C supplementation, it's important to weigh them against those of conventional OUD medications like methadone, buprenorphine, naltrexone, and naloxone. Standard OUD medications can cause various side effects, including sedation, respiratory depression, cardiac arrhythmias, hormonal disruption, and serious reactions like depression or hepatotoxicity. While these medications have evidence supporting their long-term efficacy, they often focus on maintenance rather than resolving underlying tolerance and dependency. In comparison, vitamin C presents a significantly lower risk profile with fewer side effects.
Conclusion and Recommendations
Vitamin C supports neurological and neuroendocrine functions, making it vital for pain management and OUD treatment.
The highest concentrations of Vitamin C are found in the nervous and neuroendocrine tissues, areas critical for synthesizing hormones like cortisol, neurotransmitters, and neuropeptide hormones. Its versatile properties as an antioxidant, anti-inflammatory, analgesic, and neuromodulator underscore its essential role in these biochemical functions, positioning it as a key nutrient in addressing pain and opioid use disorder (OUD).
Vitamin C can assist in OUD management through pain mitigation, preventing opioid tolerance/dependency, and facilitating withdrawal.
Vitamin C offers at least three potential applications in combating OUD and the opioid crisis: 1) Mitigating pain and preventing opioid tolerance and dependency when administered proactively during surgery, injury, or stressful periods. 2) Assisting patients in comfortably tapering off opioids. 3) Making abrupt opioid discontinuation (cold turkey) more manageable and successful.
Vitamin C is an affordable, available, and well-tolerated option that can be safely administered at home, unlike many OUD interventions.
Compared to many current interventions for OUD, Vitamin C is affordable, widely accessible, and generally well-tolerated, especially in its buffered sodium ascorbate (SA) form. It can be safely administered orally at home for most patients. Given its minimal side effects and numerous collateral health benefits, SA supplementation is more likely to benefit patients than cause harm, though specific precautions are needed for individuals with certain medical conditions.
Vitamin C can be a vital component of a comprehensive OUD treatment plan, potentially acting as a catalyst for healing.
An effective approach to treating OUD requires an interdisciplinary strategy that supports withdrawal, extinguishes dependency, addresses underlying causes (biochemical, nutritional, physical, socioeconomic, mental/emotional), and prevents relapse. Vitamin C can be a crucial element in such a comprehensive plan, potentially mitigating cravings, reducing withdrawal symptoms, and addressing common nutritional and metabolic factors contributing to illness. While it may not be a sole cure, it can serve as a powerful catalyst for healing.
Further clinical trials are warranted for Vitamin C's role in pain and OUD, with initial administration before surgery and as an OUD adjuvant recommended.
Given the high mortality rate from opioid overdose, it is imperative to utilize all effective, low-risk interventions. More clinical trials are needed to explore the full potential of Vitamin C in mitigating pain and treating OUD. The author recommends two immediate, low-cost, low-risk applications: routinely administering vitamin C or SA to patients before surgical procedures and using high-dose SA as an adjunct in OUD treatment.
Ask a Question
*Uses 1 Wisdom coin from your coin balance
Past Questions
Watch / Source Article
Vitamin C, Pain and Opioid Use Disorder - PMC
Read the original web article directly on pmc.ncbi.nlm.nih.gov
Open Web Note Link
